Stock comparison
Haemonetics
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 75B | IDXX |
| Benjamin Graham | 85A | 80A | HAE |
| Philip Fisher |
Side-by-side metrics
| Metric | HAE | IDXX |
|---|---|---|
| Market cap | $2.98B | $44.06B |
| P/E (TTM) | 24.8x | 39.0x |
| EV/EBIT | 14.1x | 31.6x |
| ROIC (TTM) | 8.37% | 40.66% |
| Gross margin | 55.74% | 62.05% |
| Net margin | 7.29% | 24.63% |
| Revenue CAGR 5y | 7.65% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 10.79%+56%
- EV/EBIT14.1xvs 31.6x+55%
- P/E (TTM)24.8xvs 39.0x+36%
IDXX leads on
More like IDXX
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.